InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Krystal Biotech, Inc.

KRYS Clue Score76
United States Fiscal year ends December CIK 0001711279 Results filed 2 Nov 2026
Add to watchlist

What the insiders did Net selling

Individual transactions

27
Insider
Date
Role
Action
Shares
Price
Amount
John Charles Thomas
25 Jun 2026
EVP, General Counsel
Sold after exercise
1,000
$347.27
$347.27K
Daniel Janney
24 Feb 2026
Director
Sold after exercise indirect
2,425
$274.90
$666.63K
Daniel Janney
24 Feb 2026
Director
Sold after exercise indirect
930
$269.50
$250.64K
Daniel Janney
24 Feb 2026
Director
Sold after exercise indirect
1,674
$268.67
$449.75K
Daniel Janney
24 Feb 2026
Director
Sold after exercise indirect
1,891
$267.37
$505.60K
Daniel Janney
24 Feb 2026
Director
Sold after exercise indirect
4,339
$266.62
$1.16M
Daniel Janney
24 Feb 2026
Director
Sold after exercise indirect
1,604
$265.54
$425.92K
Daniel Janney
24 Feb 2026
Director
Sold after exercise indirect
900
$264.60
$238.14K
Daniel Janney
24 Feb 2026
Director
Sold after exercise indirect
62
$263.05
$16.31K
Daniel Janney
24 Feb 2026
Director
Sold after exercise
373
$271.09
$101.12K
Daniel Janney
24 Feb 2026
Director
Sold after exercise
370
$269.83
$99.84K
Daniel Janney
24 Feb 2026
Director
Sold after exercise
3,963
$268.97
$1.07M
Daniel Janney
24 Feb 2026
Director
Sold after exercise
6,671
$268.04
$1.79M
Daniel Janney
24 Feb 2026
Director
Sold after exercise
11,673
$266.97
$3.12M
Daniel Janney
24 Feb 2026
Director
Sold after exercise
8,986
$266.18
$2.39M
Daniel Janney
24 Feb 2026
Director
Sold after exercise
3,557
$265.08
$942.88K
Daniel Janney
24 Feb 2026
Director
Sold after exercise
1,733
$264.12
$457.73K
Daniel Janney
24 Feb 2026
Director
Sold after exercise
569
$262.91
$149.59K
Dino A Rossi
19 Feb 2026
Director
Sold after exercise
10,834
$262.10
$2.84M
Dino A Rossi
19 Feb 2026
Director
Sold after exercise
8,116
$260.49
$2.11M
Kathryn Romano
9 Feb 2026
Chief Accounting Officer
Sold after exercise
96
$277.88
$26.68K
Kathryn Romano
9 Feb 2026
Chief Accounting Officer
Sold after exercise
400
$275.68
$110.27K
Kathryn Romano
9 Feb 2026
Chief Accounting Officer
Sold after exercise
552
$274.64
$151.60K
Kathryn Romano
9 Feb 2026
Chief Accounting Officer
Sold after exercise
928
$273.71
$254.00K
Kathryn Romano
9 Feb 2026
Chief Accounting Officer
Sold after exercise
2,824
$272.51
$769.56K
Kathryn Romano
9 Feb 2026
Chief Accounting Officer
Sold after exercise
5,700
$271.66
$1.55M
Kathryn Romano
9 Feb 2026
Chief Accounting Officer
Sold after exercise
2,000
$270.56
$541.12K
Showing 250 of 572 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 160
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 341
Sales straight out of an exercise 68
Sales at will 150
Transactions with no price 0
Shares from compensation/vesting 1,370,174
Sales filed before the plan box existed 121
History held since 25 Sep 2017